QNCX
Quince Therapeutics Inc.
$1.62
+$0.02(+1.25%)
58
Overall
--
Value
58
Tech
--
Quality
Market Cap
$85.94M
Volume
245.43K
52W Range
$0.69 - $2.45
Target Price
$7.40
Order:
Income Statement
| Metric | Trend | Chart | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | ||||||||
| Operating Expenses | $39.2M | $78.9M | $90.3M | $51.2M | $34.6M | $57.3M | ||
| Research & Development | $30.2M | $61.3M | $60.8M | $25.2M | $9.4M | $18.6M | ||
| Research Expense | $30.2M | $61.3M | $60.8M | $25.2M | $9.4M | $18.6M | ||
| Selling, General & Administrative | $9.0M | $17.6M | $29.5M | $26.0M | $17.7M | $17.6M | ||
| General & Administrative Expenses | $9.0M | $17.6M | $29.5M | $26.0M | $17.7M | $17.6M | ||
| Salaries & Wages | -- | -- | -- | -- | $5.2M | $4.7M | ||
| Depreciation & Amortization | $188.0K | $332.0K | $344.0K | $200.0K | $300.0K | $200.0K | ||
| Depreciation & Amortization | $188.0K | $332.0K | $344.0K | $200.0K | $300.0K | $200.0K | ||
| Amortization | $107.0K | $230.0K | $220.0K | $50.0K | $17.6M | -- | ||
| Other Operating Expenses | $-535.0K | $-917.0K | $-1.3M | $-825.0K | $-451.0K | $-100.0K | ||
| OPERATING INCOME | ||||||||
| Operating income | $-39.2M | $-78.9M | $-90.3M | $-50.4M | $-34.6M | $-57.3M | ||
| EBITDA | $-36.8M | $-78.6M | $-89.6M | $-50.4M | $-31.3M | $-56.6M | ||
| NON-OPERATING ITEMS | ||||||||
| Intinc | $2.2M | $2.0M | $620.0K | $1.1M | $3.5M | $2.9M | ||
| Net Non-Operating Interest Income/Expense | $2.2M | $2.0M | $620.0K | $1.1M | $3.5M | $2.9M | ||
| Gain on Sale of Securities | $2.2M | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-2.2M | -- | $247.0K | $-1.8M | $6.0M | $676.0K | ||
| Other Special Charges | -- | -- | $-247.0K | $-997.0K | $-102.0K | $-676.0K | ||
| SPECIAL ITEMS | ||||||||
| Restructring And Mn A Income | -- | -- | $96.1M | $52.6M | $300.0K | -- | ||
| Special Income Charges | -- | -- | $-96.1M | $-53.4M | $-400.0K | $-17.1M | ||
| Impairment of Capital Assets | -- | -- | -- | $825.0K | $100.0K | $17.1M | ||
| PRE-TAX INCOME | ||||||||
| EBIT | $-37.0M | $-78.9M | $-89.9M | $-50.6M | $-31.6M | $-56.7M | ||
| Pre-Tax Income | $-37.0M | $-76.8M | $-89.9M | $-50.3M | $-29.7M | $-51.0M | ||
| INCOME TAX | ||||||||
| Tax Provision | -- | -- | -- | $-284.0K | $-197.0K | $87.0K | ||
| NET INCOME | ||||||||
| Net Income | $-37.0M | $-76.8M | $-89.9M | $-50.0M | $-31.4M | $-56.8M | ||
| Net Income (Continuing Operations) | $-37.0M | $-76.8M | $-89.9M | $-50.3M | $-31.4M | $-56.8M | ||
| Net Income (Discontinued Operations) | $-37.0M | $-76.8M | $-89.9M | $-50.0M | $-31.4M | $-56.8M | ||
| Net Income (Common Stockholders) | $-37.0M | $-76.8M | $-89.9M | $-50.0M | $-31.4M | $-56.8M | ||
| Normalized Income | -- | -- | -- | -- | -- | $-33.4M | ||
| TOTALS | ||||||||
| Total Expenses | $39.2M | $78.9M | $90.3M | $51.2M | $34.6M | $57.3M | ||
| SHARE & EPS DATA | ||||||||
| Average Shares Outstanding | $19.0M | $29.2M | $29.7M | $33.5M | $37.2M | $43.3M | ||
| Average Shares Outstanding (Diluted) | $19.0M | $29.2M | -- | $33.5M | $37.2M | $43.3M | ||
| Shares Outstanding | $29.4M | $29.6M | $30.1M | $36.3M | $43.2M | $44.0M | ||
| Basic EPS | $-1.94 | $-2.63 | $-3.03 | $-1.54 | $-0.84 | $-1.31 | ||
| Basic EPS (Continuing Operations) | $-1.94 | $-2.63 | $-3.03 | $-1.54 | $-0.84 | $-1.31 | ||
| Diluted EPS | $-1.94 | $-2.63 | $-3.03 | $-1.54 | $-0.84 | $-1.31 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-1.54 | $-0.84 | $-1.31 | ||
| OTHER METRICS | ||||||||
| Acquisition Expense | -- | -- | -- | $2.2M | $2.5M | -- | ||
| Net Income From Other Gains Losses | -- | -- | -- | $284.0K | -- | -- | ||
| Other Gand A | $9.0M | $17.6M | $29.5M | $26.0M | $17.7M | $17.6M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | $5.9M | -- | ||
| Restruct | -- | -- | $96.1M | $52.6M | $300.0K | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | QNCX | $1.62 | +1.3% | 245.43K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Quince Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW